Low — 0 expert voices, 0 KB claims. This is a quant/fundamentals call, not an expert-panel call
Position sizing
Satellite income/value sleeve, ~1–3% weight (not a core compounder)
Next catalyst
2026-08-06 Q2'26 earnings (Street revenue ~$7.4B)
Single biggest risk
HIV concentration (~70% of revenue) into the early-2030s Biktarvy patent cliff
One-line thesis. Gilead is a cheap, cash-gushing HIV franchise (79% gross margin, 6.3% FCF yield, 2.45% dividend, 1.0× net-debt/EBITDA) trading at ~18× earnings — a defensive income-and-value holding whose entire re-rating case rests on lenacapavir/Yeztugo extending the HIV moat past the Biktarvy cliff, with no expert-panel conviction behind it.
◆ Synthos call — Buy — TacticalGILD offers ~11% upside to fair value (~$146) with the trend confirming — buy $130–$131, take profits toward $146, and exit on a close below the 200-day (~$130).
Downside Risk (lower = safer)
3/10 · Low
Cheap (17.7× TTM, 12.7× EV/EBITDA), 1.0× net-debt/EBITDA, 0.33 beta — but a ~70%-of-revenue HIV concentration into a 2030s Biktarvy cliff.
Growth Quality
5/10 · Moderate
Only ~6% forward revenue and ~10% EPS CAGR, but 79% gross margin, 42% ROE and a durable HIV moat.
Exponential Potential
3/10 · Low
Lenacapavir (Yeztugo) PrEP is a real new leg, but low-single-digit top line and a mature $163B cap cap the multibagger.
◆ Target entry zone$130 – $131accumulate in this band; ideal adds on a dip toward the 200-day average near $130, keeping roughly a 10% margin below our $146 base-case fair value⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 60%/yrTo justify today’s $131, earnings would have to compound roughly 60% a year for 10 years (9% discount rate). Analysts forecast ~48%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Gilead makes the medicines that keep HIV under control — its drug Biktarvy is taken by a huge share of HIV patients worldwide, and HIV is roughly 70 cents of every sales dollar. It also sells cancer cell-therapies (Yescarta), a breast-cancer drug (Trodelvy), and the COVID drug Veklury.
The stock is cheap, not expensive. You're paying about $18 for every $1 of annual profit — far less than a fast-growing drugmaker — and while you wait you collect a ~2.5% dividend. The trade-off: the business barely grows (sales rose only ~2% last year), so this is a "get paid to wait" holding, not a rocket.
Our verdict is Buy as a small "satellite" position — a steady income/value holding on the side, not a big core bet. Important honesty note: no expert in our research library covers this stock, so this call rests purely on the numbers, not on any analyst conviction.
Here's what our three scores mean in everyday terms:
Downside Risk 3/10 (fairly safe). Cheap, low debt, and the stock barely moves with the market — but too much of the business rides on one disease area.
Growth Quality 5/10 (middling). Very profitable, but growing slowly.
Exponential Potential 3/10 (low). A big, mature company in a mature market — don't expect it to double soon.
The one big worry: Gilead's cash-cow HIV drug Biktarvy loses patent protection in the early 2030s. The whole story depends on its newer long-acting HIV drug, lenacapavir, taking over before that happens.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = GILD · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$131.27
Market cap$163B
P/E trailing6×
P/E FY26E / FY27E-164× / 14×
EV / Sales6.0×
EV / EBITDA12.7×
Gross margin79.4%
Net margin31.0%
Dividend yield2.45%
Beta0.331
52-wk range$108 – $156
RSI(14)62
50 / 200-DMA$130 / $130
12-mo return+17% (SPY +21%)
Street target$162 ($122–$180)
Analyst grades38 Buy · 19 Hold · 1 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on GILD · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Gilead Sciences (Nasdaq: GILD) is a ~$163B-cap global biopharma founded in 1987 and headquartered in Foster City, CA, led by CEO Daniel O'Day. Its identity is the antiviral franchise — it is the dominant force in HIV (Biktarvy, Descovy, the Truvada/Genvoya family, and now the long-acting lenacapavir), with additional legs in oncology / cell therapy (Yescarta and Tecartus in CAR-T; Trodelvy in breast/urothelial cancer), COVID (Veklury), and liver disease (the historic HCV/HBV portfolio). Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
By product line: Other HIV $20.75B (~70%) · Cell Therapy $2.18B · Trodelvy $1.40B · Veklury $0.91B · Other $0.80B. The single most important fact about Gilead is that it is, first and foremost, an HIV company — the concentration is both the moat and the risk.
By geography: United States $20.88B (~71%) · Europe $5.06B · Other International $3.50B. Heavily US-weighted, which is a pricing-power strength and a US-drug-pricing-policy risk (§11).
The strategic pivot to watch is lenacapavir (brand Yeztugo) — a twice-yearly long-acting agent approved for both HIV treatment and, critically, PrEP (pre-exposure prophylaxis / prevention). It is the designated successor that must carry the HIV franchise across the early-2030s Biktarvy patent cliff and open a large new prevention market.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert thesis to report.total_claims = 0 for GILD in the Synthos knowledge base: zero net-bullish voices, zero cautionary voices, zero traceable claim_ids. Unlike our conviction-track names (where a broad expert panel drives the call), GILD has no expert coverage in the KB at all.
Per the Synthos house standard, we say this plainly rather than manufacture conviction: this verdict is entirely fundamentals- and quant-driven. Every number below comes from Gilead's filings and live FMP consensus estimates; none of it is backed by a distilled expert claim. Read the Buy — Tactical verdict accordingly: it reflects a cheap, defensible cash-flow profile, not a chorus of experts pounding the table.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
3 · Low-Moderate
Cheap (17.7× TTM, 12.7× EV/EBITDA), 1.0× net-debt/EBITDA, 0.33 beta, 6.3% FCF yield, 2.45% dividend cushion, only −15.7% off the high. The offset: ~70%-of-revenue HIV concentration into the early-2030s Biktarvy cliff.
Growth Quality
5 · Moderate
79% gross margin, 42% ROE, 20% ROIC — elite profitability — but only ~6% forward revenue CAGR and ~10% EPS CAGR. High-quality earnings, low-quality growth.
Exponential Potential
3 · Low
Low-single-digit, decelerating-to-flat top line at a mature $163B cap. Lenacapavir PrEP is a genuine new leg, but it defends the franchise more than it multiplies it. A small accelerator this is not.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Lenacapavir/Yeztugo PrEP ramps fast and expands the HIV TAM; Trodelvy + cell therapy add growth; oncology pipeline de-risks. FY27E adj EPS beats to ~$10.50 (vs ~$9.70 cons); multiple re-rates to ~17×.
~$179 (+36%)
Base(our anchor)
Estimates roughly hit — FY27E adj EPS ~$9.70; a durable-but-slow HIV compounder with 79% GM earns a ~15× multiple.
~$146 (+11%)
Bear
HIV pricing/volume erosion, lenacapavir uptake disappoints, or generics/biosimilars and US pricing bite ahead of the cliff. FY27E adj EPS misses to ~$8.50; multiple de-rates to ~12×.
~$102 (−22%)
Synthos fair value = the base case, ~$146 (+11%), with the full $102–$179 span as the honest range. Our anchor sits below the Street's $161.81 consensus — we give less benefit-of-the-doubt to the lenacapavir ramp and take the concentration/cliff seriously — and our bear ($102) is near the Street's $122 low. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). GILD is neither an exponential nor even a fast compounder — it is a cheap, mature cash machine:
Forward growth: revenue CAGR FY25→FY30E ~5.6% ($29.4B → $38.7B); adj-EPS CAGR ~10% ($8.11 FY25 est → $13.11 FY30E), the gap coming from margin/buyback rather than volume.
Acceleration (the 2nd derivative) is roughly flat-to-negative: revenue has been range-bound near $27–29B for five years (FY21 $27.3B → FY25 $29.4B). There is no inflection here — the top line grinds, it does not accelerate.
Room to run: HIV is a mature, well-penetrated market. Lenacapavir PrEP genuinely expands the prevention TAM, and that is the one real new leg — but at a $163B cap in a slow category, a multibagger is not on the table. This is a defensive holding, not a room-to-run story.
Reinvestment runway: modest capex (~$0.6B/yr, <2% of revenue) and heavy return-of-capital (~$4.0B dividends + ~$1.9B buyback FY25). The capital story is return cash, not reinvest for hypergrowth.
Exponential Potential: Low (3/10). Own GILD for cheap, defensible cash flow and a ~2.5% dividend, not for growth. That honest framing is why it belongs in a satellite income/value sleeve, not a growth core.
Margins: gross 79.4% TTM, EBITDA 47.1% TTM, operating ~38%, net 31.0% TTM. Best-in-class profitability; the moat shows up in margin, not growth.
Earnings (mind the GAAP noise): FY25 net income $8.51B, EPS $6.84 (diluted $6.78) — a clean year. FY24 EPS was just $0.38, crushed by a ~$4.2B Q1'24 CymaBay IPR&D charge; FY23 EPS was $4.54. Watch the FY26 GAAP estimate: consensus net income is negative (−$0.80 EPS) and the Aug-2026 quarter carries a −$7.14 GAAP EPS estimate — that is a large one-time acquisition/IPR&D charge, not operating deterioration. Q1'26 GAAP EPS was $1.63; adjusted was $2.03 (per the earnings calendar). Use adjusted EPS for valuation; GAAP is distorted by deal charges.
Cash flow: operating CF $10.0B, capex −$0.56B, FCF $9.46B FY25 (6.3% FCF yield). Cash generation is the whole point of the stock.
Balance sheet: cash & ST investments $10.6B, total debt $24.6B, net debt $17.0B, net-debt/EBITDA ~1.0× — comfortably investment-grade, easily serviceable against ~$13.6B EBITDA. Intangibles/goodwill $25.3B (44% of assets) reflect the acquisition-heavy strategy.
6. Valuation — priced in or room?
Gilead is genuinely cheap on almost every lens: 17.7× TTM EPS, ~16× FY27E adjusted, 6.0× EV/sales, 12.7× EV/EBITDA, 15.9× P/FCF, 6.3% FCF yield, 2.45% dividend yield. The FMP letter rating is B+ and PEG screens low (~0.32 TTM). That is the value case in one line: you are paying a below-market multiple for elite margins and a fortress balance sheet.
The honest counterweight is why it's cheap: ~6% revenue growth and a concentrated HIV base facing a 2030s cliff. The re-rating case is that lenacapavir/Yeztugo extends and expands the franchise, letting the multiple drift from ~13× EV/EBITDA toward the high-teens P/E the market grants durable pharma. A reverse read: at ~16× FY27E adjusted, the market is pricing modest growth and some cliff risk — not a disaster, not a re-rating. Street targets (context): consensus $161.81, high $180, low $122 (38 Buy / 19 Hold / 1 Sell). Our $146 base is below consensus because we haircut the lenacapavir ramp and respect the concentration. Not expensive; a cheap-cash-flow-with-an-overhang buy.
7. Technicals (computed from EOD price history)
Trend:neutral / rangebound. $131.27 sits essentially on top of both the 50-DMA ($129.60) and 200-DMA ($129.92) — the two averages are flat and nearly identical, the signature of a stock going sideways. MACD −0.80 (mildly negative).
Location:−15.7% off the 52-week high ($155.80), +21.3% off the 52-week low ($108.22); max drawdown from peak −15.7% — a middling location in a wide-ish range.
Momentum: RSI(14) 62 — firm but not overbought (<70). Note the print reflects a +4.2% up day (price $131.27 vs prior close $125.97), so near-term momentum is constructive off a base.
Relative strength (the tell): GILD +17.5% 12-mo vs SPY +20.6% and QQQ +30.3%; and −6.4% 3-mo vs SPY +13.7% / QQQ +22.0%. A laggard — it has underperformed both the market and the Nasdaq-100 over 3- and 12-month windows. This is a value/defensive profile, not a leadership name.
Read: technicals are neutral-to-slightly-improving off a base — no uptrend to confirm the thesis, but no breakdown either. Consistent with a sideways income/value holding; the fundamental cheapness, not the chart, is the reason to own it.
8. Moat & competitive position
Gilead's moat is HIV franchise dominance: Biktarvy is the most-prescribed HIV regimen in its markets, and the switching costs, guideline entrenchment, and 30-year antiviral R&D base are real barriers. Lenacapavir's twice-yearly dosing is a genuine best-in-class differentiator for both treatment and prevention, and Gilead's CAR-T (Yescarta/Tecartus) and Trodelvy give secondary oncology legs. The vulnerability is the flip side of the strength: concentration. ~70% of revenue in one disease area means the early-2030s Biktarvy loss-of-exclusivity is an existential-scale event that lenacapavir must offset — and ViiV/GSK (long-acting cabotegravir) competes directly in both treatment and PrEP.
Peer set (market cap, from FMP): Merck $320B, Novo Nordisk $224B, Amgen $202B, Pfizer $139B, Danaher $140B, Bristol-Myers Squibb $119B, GSK $107B, Sanofi $104B — plus device names Stryker $125B and Boston Scientific $67B. Among big pharma, GILD is mid-cap and cheaper than most on EV/EBITDA, reflecting its slower growth and concentration. It is the value end of the group, not the growth end.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-led — FY25 returned ~$4.0B in dividends and ~$1.9B in buybacks against $9.46B FCF, while paying down ~$1.8B of debt. Capex is minimal (~$0.56B). Bolt-on M&A (the CymaBay-type deals that drive the GAAP charges) is the growth-supplement lever. This is a return-cash allocator, appropriate for a mature franchise.
Insider activity: routine executive sales in the sampled window — CEO Daniel O'Day sold small blocks (11,900 + 3,100 sh) around $126–127 on 2026-07-01, CFO Andrew Dickinson and the Chief Commercial Officer sold small blocks mid-June near $123–125, and the CMO's activity was routine RSU vesting. These read as normal Rule-10b5-1 diversification, not a discretionary-selling cluster — but they are net sales at prices near today's, worth noting.
Guidance: management's dated forward guidance is not ingested as a weighted KB voice for GILD (the name has no KB coverage at all). Treat the Street consensus in §5–6 as the forward anchor. Gap flagged: adjusted-vs-GAAP reconciliation and full guidance detail would come from the earnings release / transcript, not on our current FMP plan.
10. Catalysts & what to watch
Next earnings: 2026-08-06 (Q2'26; Street revenue ~$7.4B). The −$7.14 GAAP EPS estimate signals a large one-time charge that quarter — focus on adjusted EPS, HIV net revenue, and lenacapavir/Yeztugo launch metrics, not the GAAP headline.
Lenacapavir/Yeztugo PrEP uptake: prescription trends and payer coverage — the single biggest swing factor for both the bull case and the cliff defense.
HIV base durability: Biktarvy volume and gross-to-net vs ViiV's long-acting competition.
Oncology: Trodelvy label expansion and cell-therapy (Yescarta) trajectory — the diversification leg.
Capital return: dividend growth and buyback pace as evidence the cash engine is intact.
Thesis tripwires (what would change the call): two consecutive quarters of HIV volume decline; a clearly disappointing lenacapavir PrEP ramp; net margin compression below ~28% from US pricing; or FCF falling materially below the ~$9B run-rate that funds the dividend.
11. Key risks
HIV concentration + patent cliff (structural, the dominant risk): ~70% of revenue in HIV, with Biktarvy loss-of-exclusivity in the early 2030s. Lenacapavir must carry the franchise across the cliff — if it stumbles, there is no second $20B leg.
Competition: ViiV/GSK long-acting cabotegravir competes directly in HIV treatment and PrEP; generics/biosimilars loom post-cliff.
US pricing policy: ~71% US revenue concentration → exposed to drug-pricing politics, IRA negotiation, and PBM/formulary friction.
GAAP noise / deal risk: acquisition-driven IPR&D charges (CymaBay-type) repeatedly distort GAAP earnings (FY24 and the FY26 estimate both negative/depressed) — capital-allocation execution on M&A matters.
No expert corroboration: unlike our conviction names, zero KB voices vet this thesis. The call is quant/fundamentals only; there is no panel to catch a blind spot.
Low growth de-rating: if lenacapavir underwhelms, a low-growth mature pharma can trade to ~11–12× EV/EBITDA — the bear case.
12. Verdict, position sizing & monitoring
Buy — Tactical. Gilead is a cheap (17.7× TTM, 12.7× EV/EBITDA), fortress-balance-sheet (1.0× net-debt/EBITDA), high-FCF (6.3% yield) HIV cash machine paying a ~2.5% dividend, with real — if bounded — optionality in lenacapavir/Yeztugo PrEP. Our base-case fair value ~$146 (+11%) sits below the Street's $161.81, and we hold this with Low conviction by design: there is zero expert coverage in the Synthos KB, so this is a numbers-driven value/income call, not a conviction call.
Sizing:satellite income/value, ~1–3% of the flagship — a "get paid to wait" holding, not a core compounder. The dividend and cheapness argue for patient accumulation on weakness rather than chasing.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print, with special attention to lenacapavir uptake and adjusted (not GAAP) EPS. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $131.27.
Single biggest risk: the HIV concentration into the early-2030s Biktarvy patent cliff — the whole verdict depends on lenacapavir extending the franchise in time.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — GILD has no expert coverage in the Synthos knowledge base. No claim_ids are cited because none exist; fabricating conviction is structurally prohibited by the house standard. This is a fundamentals/quant call.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates. Adjusted-vs-GAAP EPS distinction flagged where it matters (FY24, FY26E, Q2'26E carry large one-time deal charges).
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").